Annovis Bio Inc Total Liabilities
Annovis Bio Inc total liabilities. Based on the latest financial reports, Annovis Bio Inc (ANVS) has total liabilities worth $13.12 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See ANVS days of operational coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Annovis Bio Inc (2009–2025)
Total liabilities of Annovis Bio Inc from 2009 to 2025. This chart illustrates how Annovis Bio Inc's total liabilities have evolved over time, based on quarterly financial data.
Annovis Bio Inc Competitors by Total Liabilities
The table below lists competitors of Annovis Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DRGEM Corporation
KQ:263690
|
Korea | ₩33.57 Billion |
|
Gigas Hosting S.A
MC:GIGA
|
Spain | €129.88 Million |
|
George Kent (Malaysia) Bhd
KLSE:3204
|
Malaysia | RM176.73 Million |
|
I Yuan Precision Ind Co Ltd
TWO:2235
|
Taiwan | NT$242.09 Million |
|
Source Rock Royalties Ltd
V:SRR
|
Canada | CA$583.71K |
|
Sunndal Sparebank
OL:SUNSB
|
Norway | Nkr4.92 Billion |
|
Fleming Properties AB
ST:FLMNG
|
Sweden | Skr59.73 Million |
|
Kriti Nutrients Limited
NSE:KRITINUT
|
India | Rs-2.29 Billion |
Liability Composition Analysis (2009–2025)
This chart breaks down Annovis Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Annovis Bio Inc (ANVS) total assets.
Liquidity & Leverage Metrics
Annovis Bio Inc Total Liabilities Ratios Explained
Annovis Bio Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 4.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.81 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Annovis Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Annovis Bio Inc (2009–2025)
The table below shows the annual total liabilities of Annovis Bio Inc from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.23 Million | -8.39% |
| 2024-12-31 | $4.62 Million | -74.29% |
| 2023-12-31 | $17.96 Million | +133.28% |
| 2022-12-31 | $7.70 Million | +411.02% |
| 2021-12-31 | $1.51 Million | +160.47% |
| 2020-12-31 | $578.38K | -94.03% |
| 2019-12-31 | $9.69 Million | +26.80% |
| 2018-12-31 | $7.64 Million | +4.39% |
| 2017-12-31 | $7.32 Million | +4100.16% |
| 2012-12-31 | $174.36K | -97.54% |
| 2011-12-31 | $7.09 Million | +27.64% |
| 2010-12-31 | $5.55 Million | +12106.45% |
| 2009-12-31 | $45.49K | -- |
About Annovis Bio Inc
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury… Read more